Your browser is no longer supported. Please, upgrade your browser.
ANAB AnaptysBio, Inc. daily Stock Chart
AnaptysBio, Inc.
Index- P/E- EPS (ttm)-1.18 Insider Own1.20% Shs Outstand25.00M Perf Week14.85%
Market Cap2.02B Forward P/E- EPS next Y-3.08 Insider Trans-9.91% Shs Float23.09M Perf Month-9.67%
Income-26.10M PEG- EPS next Q-0.71 Inst Own- Short Float8.87% Perf Quarter-26.20%
Sales10.00M P/S201.88 EPS this Y-438.10% Inst Trans1.93% Short Ratio4.99 Perf Half Y-9.01%
Book/sh12.37 P/B6.53 EPS next Y-1.30% ROA-15.00% Target Price142.40 Perf Year240.43%
Cash/sh9.93 P/C8.13 EPS next 5Y- ROE-16.60% 52W Range20.12 - 134.00 Perf YTD-19.83%
Dividend- P/FCF- EPS past 5Y- ROI-6.60% 52W High-41.60% Beta-
Dividend %- Quick Ratio17.60 Sales past 5Y- Gross Margin- 52W Low288.92% ATR4.39
Employees60 Current Ratio17.60 Sales Q/Q- Oper. Margin- RSI (14)47.99 Volatility6.36% 5.70%
OptionableYes Debt/Eq0.05 EPS Q/Q15.20% Profit Margin- Rel Volume0.40 Prev Close80.75
ShortableYes LT Debt/Eq0.02 EarningsMay 10 Payout- Avg Volume410.60K Price78.25
Recom1.80 SMA201.36% SMA50-8.06% SMA200-7.43% Volume63,105 Change-3.10%
Apr-04-18Downgrade RBC Capital Mkts Outperform → Sector Perform
Mar-27-18Reiterated Stifel Buy $139 → $152
Mar-06-18Reiterated Stifel Buy $130 → $139
Feb-15-18Reiterated SunTrust Buy $115 → $162
Jan-23-18Reiterated Credit Suisse Outperform $85 → $135
Nov-15-17Initiated SunTrust Buy $115
Nov-09-17Initiated Jefferies Buy $101
Oct-11-17Reiterated RBC Capital Mkts Outperform $40 → $79
Sep-15-17Initiated RBC Capital Mkts Outperform $40
Jul-11-17Initiated Robert W. Baird Outperform $36
Feb-21-17Initiated Wedbush Outperform $28
Feb-21-17Initiated Stifel Buy $30
Feb-21-17Initiated JMP Securities Mkt Outperform $45
Feb-21-17Initiated Credit Suisse Outperform $34
Jun-07-18 02:00PM  Soaring No-Name Stocks Signal a Market Top Investopedia
May-30-18 06:30AM  AnaptysBio to Present at the Jefferies 2018 Global Healthcare Conference GlobeNewswire
May-29-18 08:30AM  AnaptysBio Presents Updated ANB020 and ANB019 Clinical Data at the 2018 EAACI Congress GlobeNewswire
May-18-18 08:25AM  Market Trends Toward New Normal in Castlight Health, inc, Marriot Vacations Worldwide, AnaptysBio, Compass Diversified, Triumph, and Asbury Automotive Group Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
May-09-18 03:48PM  AnaptysBio Sets the Stage for an Eventful Year Motley Fool
May-08-18 04:15PM  AnaptysBio Announces First Quarter 2018 Financial Results and Provides Pipeline Updates GlobeNewswire
May-01-18 06:30AM  AnaptysBio Announces ANB020 and ANB019 Clinical Data Presentations at the 2018 EAACI Congress GlobeNewswire
Apr-27-18 06:30AM  AnaptysBio To Participate in Upcoming Investor Conferences GlobeNewswire +6.22%
Apr-05-18 04:55PM  Here's What Pressured AnaptysBio Inc. Again Today Motley Fool -7.45%
Apr-02-18 06:52PM  Is This Why AnaptysBio Inc. Fell on Monday? Motley Fool -9.67%
Mar-29-18 07:50AM  Blog Exposure - Nabriva Therapeutics Collaborated with Roivant to Commercialize Lefamulin in Greater China ACCESSWIRE
Mar-27-18 04:07PM  Why These Biotechs Diverged On AnaptysBio's Peanut Allergy Study Investor's Business Daily -5.54%
06:47AM  Heres Whats Moving AnaptysBio and Biohaven Pharmaceutical Market Exclusive
Mar-26-18 05:13PM  9 Stocks Moving In Monday's After-Hours Session Benzinga
04:05PM  AnaptysBio Announces Positive Top-Line Proof-of-Concept Data For ANB020 In Moderate-to-Severe Baseline Adult Peanut Allergy Patients GlobeNewswire
Mar-21-18 08:30AM  Todays Research Reports on Trending Tickers: AnaptysBio and Loxo Oncology ACCESSWIRE
Mar-20-18 07:40AM  Wired News Cellular Biomedicine's 48-Week Data off China-based Phase-I Clinical Trial Shows Positive Result for AlloJoin(TM) for Treatment of KOA ACCESSWIRE
07:40AM  Analysis: Positioning to Benefit within AnaptysBio, MoSys, CONMED, Franklin Financial Network, Hersha Hospitality Trust, and Inovalon Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Mar-18-18 10:31AM  2 Biotech Stocks Near All-Time Highs: Can They Keep Climbing? Motley Fool
Mar-15-18 07:31AM  Better Know Biotech: 3 Highfliers That Ought to Be on Your Radar Motley Fool
Mar-06-18 02:02PM  AnaptysBio Gears Up For an Eventful Year Motley Fool
Mar-05-18 04:15PM  AnaptysBio Announces Fourth Quarter and Full Year 2017 Financial Results and 2018 Pipeline Milestones GlobeNewswire -7.45%
Feb-26-18 09:25AM  George Soros Just Bought These 2 Biotech Stocks. Should You? Motley Fool
Feb-17-18 05:00PM  AnaptysBio Presents Updated Data from ANB020 Phase 2a Atopic Dermatitis Trial at AAD Annual Meeting GlobeNewswire
Feb-07-18 04:44PM  Here's Why AnaptysBio, Inc. Stock Surged on Wednesday Motley Fool +9.36%
06:30AM  AnaptysBio To Present Data from ANB020 Phase 2a Atopic Dermatitis Trial at AAD Annual Meeting GlobeNewswire
Jan-18-18 07:40AM  Investor Expectations to Drive Momentum within Martin Marietta Materials, AnaptysBio, Hope, Agilysys, Albany International, and Goldman Sachs BDC Discovering Underlying Factors of Influence GlobeNewswire
Jan-02-18 08:00AM  The Zacks Analyst Blog Highlights: AnaptysBio, , Roku, SMART Global Holdings, UroGen Pharma and Calyxt Zacks
06:30AM  AnaptysBio Announces Presentation at the J.P. Morgan 36th Annual Healthcare Conference GlobeNewswire
Dec-29-17 02:40PM  5 Best Performing IPOs of 2017 Zacks
Dec-28-17 08:23AM  The Zacks Analyst Blog Highlights: ACADIA Pharmaceuticals, Sangamo Therapeutics, AnaptysBio and Sino Biopharmaceutical Zacks
Nov-07-17 06:00AM  AnaptysBio Announces Third Quarter 2017 Financial Results and Provides Pipeline Updates GlobeNewswire
Nov-06-17 04:15PM  AnaptysBio Reports Positive ANB019 Top-line Phase 1 Clinical Trial Results GlobeNewswire
Oct-31-17 06:30AM  AnaptysBio to Participate in Upcoming Investor Conferences GlobeNewswire
Oct-12-17 06:45PM  AnaptysBio Announces Pricing of Public Offering GlobeNewswire
07:30AM  Featured Company News - AnaptysBio Announces Positive Interim Data from Phase-2a Clinical Trial of ANB020 for Treating Atopic Dermatitis ACCESSWIRE
Oct-11-17 09:46AM  Company News For Oct 11, 2017 Zacks
Oct-10-17 04:57PM  This Biotech Hit Record High; Could Undercut Regeneron In Eczema Investor's Business Daily +101.17%
04:20PM  AnaptysBio Files Registration Statement for Proposed Public Offering GlobeNewswire
11:38AM  Here's Why AnaptysBio Inc. Is Rocketing Higher Today Motley Fool
06:30AM  AnaptysBio Reports Positive Topline Proof-of-Concept Data from Phase 2a Clinical Trial of ANB020 in Atopic Dermatitis GlobeNewswire
Oct-02-17 10:40AM  ETFs with exposure to AnaptysBio, Inc. : October 2, 2017 Capital Cube
Sep-22-17 10:15AM  ETFs with exposure to AnaptysBio, Inc. : September 22, 2017 Capital Cube
Sep-18-17 02:16PM  RBC Capital's Marc Harris breaks down his best biotech pi... CNBC Videos +11.63%
Sep-11-17 08:24PM  ETFs with exposure to AnaptysBio, Inc. : September 12, 2017 Capital Cube
Sep-08-17 03:51PM  AnaptysBio, Inc. :ANAB-US: Earnings Analysis: Q2, 2017 By the Numbers : September 8, 2017 Capital Cube
Sep-01-17 10:35PM  AnaptysBio, Inc. Value Analysis (NASDAQ:ANAB) : September 2, 2017 Capital Cube +5.76%
Aug-29-17 08:36AM  AnaptysBio, Inc. breached its 50 day moving average in a Bullish Manner : ANAB-US : August 29, 2017 Capital Cube
Aug-24-17 08:00AM  AnaptysBio Announces Appointment of J. Anthony Ware, M.D. to Board of Directors GlobeNewswire +5.44%
Aug-10-17 04:30PM  AnaptysBio Announces Second Quarter 2017 Financial Results and Provides Pipeline Updates GlobeNewswire
Aug-09-17 08:57AM  Should You Buy AnaptysBio (ANAB) Ahead of Earnings? Zacks
Aug-08-17 06:30AM  AnaptysBio to Present at Wedbush PacGrow Healthcare Conference GlobeNewswire -5.49%
Jul-31-17 09:58AM  AnaptysBio, Inc. breached its 50 day moving average in a Bearish Manner : ANAB-US : July 31, 2017 Capital Cube
Jul-24-17 01:59PM  ETFs with exposure to AnaptysBio, Inc. : July 24, 2017 Capital Cube +12.07%
Jul-14-17 12:47PM  ETFs with exposure to AnaptysBio, Inc. : July 14, 2017 Capital Cube
Jul-13-17 08:53AM  AnaptysBio, Inc. breached its 50 day moving average in a Bullish Manner : ANAB-US : July 13, 2017 Capital Cube
Jun-28-17 03:18PM  AnaptysBio, Inc. Value Analysis (NASDAQ:ANAB) : June 28, 2017 Capital Cube
Jun-27-17 08:23AM  AnaptysBio, Inc. breached its 50 day moving average in a Bullish Manner : ANAB-US : June 27, 2017 Capital Cube
Jun-09-17 08:50AM  Why AnaptysBio (ANAB) Could Be Positioned for a Slump Zacks
Jun-01-17 06:30AM  AnaptysBio to Participate in Upcoming Investor Conferences GlobeNewswire
May-29-17 08:21AM  AnaptysBio, Inc. breached its 50 day moving average in a Bearish Manner : ANAB-US : May 29, 2017 Capital Cube
May-11-17 04:30PM  AnaptysBio Announces First Quarter 2017 Financial Results and Provides Pipeline Update GlobeNewswire
08:57AM  AnaptysBio, Inc. breached its 50 day moving average in a Bearish Manner : ANAB-US : May 11, 2017 Capital Cube
Apr-20-17 02:47PM  AnaptysBio, Inc. Value Analysis (NASDAQ:ANAB) : April 20, 2017 Capital Cube
Apr-19-17 08:29AM  AnaptysBio, Inc. breached its 50 day moving average in a Bearish Manner : ANAB-US : April 19, 2017 Capital Cube
Apr-06-17 08:00AM  AnaptysBio Announces First-In-Human Dosing of ANB019 GlobeNewswire
Apr-05-17 04:17PM  ETFs with exposure to AnaptysBio, Inc. : April 5, 2017 Capital Cube
Mar-30-17 04:34PM  Will Snap, MuleSoft IPOs Kick Up A Stampede Of Tech Unicorns? Investor's Business Daily
12:35PM  Q1 IPOs Raised $10 Billion
Mar-20-17 11:29AM  AnaptysBio, Inc. :ANAB-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017 Capital Cube
Mar-16-17 10:18AM  AnaptysBio, Inc. :ANAB-US: Earnings Analysis: 2016 By the Numbers : March 16, 2017 Capital Cube
Mar-14-17 01:04PM  ANAPTYSBIO INC Financials
Mar-08-17 04:33PM  ANAPTYSBIO INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:30PM  AnaptysBio Announces 2016 Operating Results and Pipeline Progress GlobeNewswire
Mar-04-17 03:00PM  AnaptysBio Announces Data from Scientific Collaboration with the Benaroya Research Institute Presented at the AAAAI 2017 Annual Meeting GlobeNewswire
Mar-02-17 06:11AM  ANAPTYSBIO INC Files SEC form 8-K, Change in Directors or Principal Officers
Feb-21-17 06:37AM  Coverage initiated on AnaptysBio by Credit Suisse, Wedbush, Stifel and JMP Securities
Feb-14-17 09:20AM  Biotech IPOs Slow As Trump-Sown Uncertainty Rattles Nerves On Wall Street Forbes
Feb-13-17 08:00AM  AnaptysBio to Present Data from ANB020 Program at Two Upcoming Medical Meetings GlobeNewswire
Feb-06-17 12:31PM  Robust Start for Pharmaceutical IPOs In 2017 Investopedia +7.47%
Feb-02-17 05:16PM  [$$] Braeburn Pharmaceuticals Puts IPO Plans On Hold The Wall Street Journal
Jan-31-17 05:00PM  AnaptysBio Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Jan-29-17 11:39PM  [$$] Shares in Two Biotechs Rise Post-IPO at The Wall Street Journal
09:38AM  IPO Market Looking for 7 Offerings This Week
Jan-27-17 02:05PM  After $97M IPO, Swiss biotech to open U.S. headquarters in Boston at
06:15AM  Cambridges Jounce raises hopes as first Mass. biotech of 2017 to go public at
Jan-25-17 07:00PM  AnaptysBio Announces Pricing of Initial Public Offering GlobeNewswire
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's proprietary anti-inflammatory pipeline includes ANB020, an anti-interleukin-33 antibody for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy, and severe adult eosinophilic asthma; ANB019, an anti-interleukin-36R antibody for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases. It also has an immuno-oncology partnership with TESARO, Inc. and TESARO Development, Inc. to develop and commercialize monospecific antibody product candidates targeting TIM-3 (TSR-022), LAG-3 (TSR-033), and PD-1 (TSR-042), as well as a bispecific antibody product candidate targeting PD-1 and LAG-3; and an inflammation partnership with Celgene Corporation to develop an anti-PD-1 agonist antibody (CC-90006) that is in Phase 1 trial. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was founded in 2005 and is based in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Suria HamzaPresident, CEOJun 08Option Exercise2.5922,42858,08927,426Jun 11 04:38 PM
Lydon NicholasDirectorApr 16Sale86.8833,0002,866,913271,106Apr 18 04:46 PM
Lydon NicholasDirectorFeb 15Option Exercise4.5516,48374,998304,106Feb 20 04:08 PM